Embed Size (px)
DESCRIPTION
Senior Research Analyst, Bhuvaneashwar Subramanian has completed extensive analysis for the Nanomedicine market. The research expert will lead a short teleconference about new findings that affect the market.
Citation preview
Nanomedicine is the Next Revolution in Healthcare
Bhuvaneashwar SubramanianSenior Research Analyst
Technical Insights-Healthcare20th August 2008
2
Scope of the Analyst Briefing
• Introduction to the field of nanobiotechnology
• Current trends in the nanotechnology industry
• Overview of the factors influencing technology trends
• Review of key technology developments in the nanobiotechnology industry
• The future directions for nanobiotechnology
3
The Emergence of Nanobiotechnology
ALL LIVING AND NON LIVING MATTER IS COMPOSED OF NANOPARTICLES
4
The Emergence of NanoBiotechnology
Nanomaterials LifesciencesNanomaterials
FullerenesNanotubesNanowires
Quantum Dots
MicroscopyCell StainingAntibody Tagging
Drug DeliveryMedical Devices
AFMLiposomal/Micellar Delivery
Optical Tweezers
Qdot Antibody Conjugation
Delivery
Dependence
Nano
Biotechnology
5
Similarities between Bio and Nanotechnology
Bio-Nano
Technology
Long incubation periodsdevelopment of
applications
A probe to the ‘Science of the Small’
Requires hugeinvestment and
high-tech equipments
Potential to form ‘Disruptive Technology’
platforms
Infused with a hypothesis
for a better future
Requires government-industry
mutual initiatives
Ethical risksHazards of emerging
technology/pitfalls
6
TRENDS IN NANOBIOTECHNOLOGY
7
Current Global Focus Areas on Nanobiotechnology
NANOBIOTECHNOLOGY
DRUG DELIVERYNANOTHERAPEUTICS
TISSUE RECONSTRUCTIONSURGICAL DEVICES
MICROSCOPY AND IMAGINGNANOARRAYS
DIAGNOSTICS
8
Research and Development Spread in Nanobiotechnology
Sourced by: Frost & Sullivan
9
DRI
VE
RS
DR
IV
ERS
Implications of nanoparticle
size
RES
TR
AI
NTS
Disconnect in the pace of innovation in academia and Industry
Possibility of targeted drug delivery
Existence of alternative therapies
Unique properties
Key Drivers and Restraints for Nanobiotechnology
RES
TR
AI
NTS
10
Challenges Issues with scaling up production
Toxicity issues withnano materials
Competition from alternative technologies
Lack of regulatory framework
Challenges for Nanobiotechnology
11
Design better
therapies
Stagnant Positive Growth
Size of Nanoparticles
Targeted drug delivery
Improved understanding
of biological systems
Existence of
alternative therapies
Toxicity of Nanoparticles
Lack of validated
clinical studies
Limited
funding
Positive Forces Opposing Forces
Regulatory concerns
Resistance from Antinano groups
Nascent Stage
Scenario Analysis of Nanobiotechnology-Current State
12
Design betterand supportive therapies
Stagnant Growth Positive Growth
Size of Nanoparticles
Targeted drug delivery
Improved understandingof biological systems
Existence of alternative therapies
Toxicity of Nanoparticles
Lack of validated clinical studies
Limited funding
Positive Forces Opposing Forces
Regulatory concerns
Limit drug developmentto nontoxic nanoparticles
Promote private funding
Promote funded clinical studies and third party evaluation
Lack of public educationPublicize research data
Lobby for Nano drugRegulatory Committee
Improved Scenario of the Nanobiotechnology Industry
13
CompetitorsSuppliers
New Entrants
Customers
Product Substitution
•Evolved technologies
•Low production costs
•Established regulatory
•Practices
•High Adoption rate
•Nascent Science
•High scope for new entrants
•Limited players, scope for research
•Availability of funding for startups
•Minimal Suppliers
•Not a core component of the nanobio
•Value chain
•Production relegated to R & D
•Nanoscience can offer supportive function
•Applications could have high impact
•Could face resistance
•from existing technologies
•Loyalty to tried and tested technologies
•Lack of widespread awareness
•Strong requirement for Proof of Principle
•Emergence of alternative technologies
•and treatment options offer hope for
nanobiotechnlogy
Porter’s Model for New Entrants in Nanobiotechnology
14
Key Developments in Nanobiotechnology
• Delivery system to target PLGA nanoparticles to arrest macular degeneration by
Charlesson LLC, USA
• DNA Programmed Chemistry(DPC) platform enables target drug discovery and development of protein detection bioassays, Ensemble Discovery Corporation, USA
• Nanospider- nanofiber technology developed by Elmarco, Spain and Alltracel, Ireland finds application as an antibacterial layer in wound dressings
• Nanovic, Australia has developed a transdermal drug delivery system-NanoMAP to deliver peptides, hormones and and therapeutic proteins through transdermal
route.
• Luminiscent nanocrystals developed from ZnO and integrated into biosensor
applications
• Nanostructured hydroxyapatite for artificial bone matrix being developed by
AngstroMedica.
• Nanomateria is developing nanostructured material for heart, cartilage and bone regeneration
• Nanocarrier, based out of Chiba Japan is developing micellar nanoparticles for insoluble drugs
15
Nanobiotechnologies at Various Stages of Commercialization
PRODUCT TYPE OF NANOMATERIAL
INDICATION PHASE COMPANY
Abraxane Nano-particle albumin
Lung cancer,breastcancer
On Market AbraxisBioscience
Combidex Iron-oxide nanoparticle
Tumor Imaging NDA Filed Advanced Magnetics
Cyclosertcamptothecin
Cyclodextrinnanoparticle
Metastatic solid tumors
IND Filed Insert Therapeutics
Verigene platform DNA-Functionalized gold nanoparticles
Diagnostic On market Nanosphere
INGN-401 Liposome Metastatic Lung Cancer
Phase-1 Introgen
Nanoxel DDS for anti cancer drug Paclitaxel
Breast,
ovarian cancer
On Market Dabur
MRX-952 formulation of irinotecanmetabolite
Oncology Preclinical ImaRxTherapeutics
16
Commercialization Time-Line of Nanobiotechnology Initiatives
Sourced by: Frost & Sullivan
17
Global Activity Distribution in Nanobiotechnology as per Organizational Setup
Sourced by: Frost & Sullivan
18
Future Activity in Nanobiotechnology by 2015 and Beyond
Sourced by: Frost & Sullivan
19
Current Trends in Nanobiotechnology
• United States and Europe lead the way in applying nanotechnology for
medical applications
• The funding from federal governments extensive collaborations and opportunities for spin-offs are the key reasons for the leadership of these countries in the field
• Asian countries serve as hubs for contract research for American and European Conglomerates
• The revenue generated from such outsourcing has slowly begun to boost the Asian economy toward investing heavily in indigenous
research and application
20
Focus on
Molecular Targeting
Technologies
TRENDS
Platform Development to
Broad Spectrum Medical Diagnostic
Instruments
Nanoparticulate
Contrast Regents
BiocompatibleNanocoatings and
Materials
Nano-Bio Technologies and Product
Development is more of “AnEvolution than Revolution”
Technology Trends in Nanobiotechnology
21
ASSESSMENT OF NANOBIOTECHNOLOGY INDEVELOPING ECONOMIES
ANDFUTURE DIRECTIONS
22
SWOT
ANALYSIS
of Nanobio
technology
Industry
In
Developing
Economies
•Young talent
•Low costs
S W
•Weak link betweenindustry and academia
• Lack of venture capital
•Weak link betweenindustry and academia
• Lack of venture capital
• Increasing
population
•Contract research
• Increasing
population
•Contract research
O
•Competition from neighboring countries
•Anti nanobio propaganda and hype
•Safety issues
•Competition from neighboring countries
•Anti nanobio propaganda and hype
•Safety issues
T
SWOT Analysis of Nanobiotechnology in Developing Economies
23
The Future of Nanaobiotechnology –Promote an Informed Lifestyle
INCREASING GERIATRIC POPULATION
RAPID DISEASE DETECTIONAND RISK
CALCULATION
NON INVASIVE TREATMENT
DIAGNOSTICS
GENETIC SUSCEPTIBILITYTO DISEASES
NANOBIO/NANOMEDTHERAPEUTICS
PROSTHETICSCONVENIENCE HEALTHCARE
24
Your Feedback is Important to Us
Growth Forecasts?
Competitive Structure?
Emerging Trends?
Strategic Recommendations?
Other?
Please inform us by taking our survey.
What would you like to see from Frost & Sullivan?
25
For Additional Information
• To leave a comment, ask the analyst a question, or receive the
free audio segment that accompanies this presentation, please contact Stephanie Ochoa, Analyst Briefing Coordinator, at (210)
247-2421 or via email, [email protected].
